Results 161 to 170 of about 1,688 (193)

Deployment and transcriptional evaluation of nitisinone, an FDA-approved drug, to control bed bugs. [PDF]

Pest Manag Sci
Sterkel M, Tompkin J, Schal C, Guerra LRM, Pessoa GCD, Oliveira PL, Benoit JB.   +6 more
europepmc   +1 more source

Hereditary Tyrosinemia Type-1 With Late Presentation: A Case Report. [PDF]

Cureus
Ilyaz M, Jadhav RS, Pande V, Mane S, Mokkarala P.   +4 more
europepmc   +1 more source

Adequacy of nitisinone for the management of alkaptonuria

Annals of Medicine and Surgery, 2022
Alkaptonuria is a rare hereditary disease with a defective enzyme that results in increased homogentisic acid levels in the body. Homogentisic acid accumulates in multiple body parts and initializes tissue damage. Clinical manifestations such as pigmentation of the skin areas and joint destruction result in ochronosis.
Khawar Abbas, Jawad Basit, Mohammad Ebad Ur Rehman   +2 more
exaly   +3 more sources

Nitisinone: a review

Orphan Drugs: Research and Reviews, 2017
A Cigdem Aktuglu-Zeybek, Tanyel Zubarioglu Department of Pediatrics, Division of Nutrition and Metabolism, Cerrahpasa Medical Faculty, Istanbul University, Kocamustafapasa Fatih, Istanbul, Turkey Abstract: Nitisinone (2-[2-nitro-4-trifluoromethylbenzoyl]cyclohexane-1,3-dione), an effective triketone herbicide, is a potent inhibitor of
Tanyel Zubarioglu
exaly   +5 more sources

Nitisinone causes acquired tyrosinosis in alkaptonuria [PDF]

Journal of Inherited Metabolic Disease, 2020
AbstractFor over two decades, nitisinone (NTBC) has been successfully used to manipulate the tyrosine degradation pathway and save the lives of many children with hereditary tyrosinaemia type 1. More recently, NTBC has been used to halt homogentisic acid accumulation in alkaptonuria (AKU) with evidence suggesting its efficacy as a disease modifying ...
Milad Khedr, Andrew T Hughes, Anna M Milan   +2 more
exaly   +3 more sources

Efficacy of low dose nitisinone in the management of alkaptonuria

Molecular Genetics and Metabolism, 2019
To study the efficacy of low dosage of nitisinone in alkaptonuria.Alkaptonuria (AKU) is a rare genetic disease which induces deposition of homogentisic acid (HGA) in connective inducing premature arthritis, lithiasis, cardiac valve disease, fractures, muscle and tendon ruptures and osteopenia.
Arnaud Wiedemann, Alain Blum, Jean-Louis GUÉant   +2 more
exaly   +3 more sources

Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre [PDF]

Molecular Genetics and Metabolism, 2018
Does Nitisinone prevent the clinical progression of the Alkaptonuria?In this observational study on 39 patients, 2 mg of daily nitisinone inhibited ochronosis and significantly slowed the progression of AKU over a three-year period.Nitisinone is a beneficial therapy in Alkaptonuria.Nitisinone decreases homogentisic acid (HGA), but has not been shown to
S Vinjamuri, J C Jarvis, A T Hughes
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

The Role of Nitisinone in Tyrosine Pathway Disorders

Current Rheumatology Reports, 2014
Nitisinone 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione (NTBC), an effective herbicide, is the licensed treatment for the human condition, hereditary tyrosinaemia type 1 (HT-1). Its mode of action interrupts tyrosine metabolism through inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD).
Lakshminarayan R Ranganath
exaly   +3 more sources